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TRPA1 is essential for the vascular response
to environmental cold exposure
Aisah A. Aubdool1, Rabea Graepel1, Xenia Kodji1, Khadija M. Alawi1, Jennifer V. Bodkin1, Salil Srivastava1,
Clive Gentry2, Richard Heads1, Andrew D. Grant2, Elizabeth S. Fernandes1, Stuart Bevan2 & Susan D. Brain1
The cold-induced vascular response, consisting of vasoconstriction followed by vaso-
dilatation, is critical for protecting the cutaneous tissues against cold injury. Whilst this
physiological reflex response is historic knowledge, the mechanisms involved are unclear.
Here by using a murine model of local environmental cold exposure, we show that TRPA1 acts
as a primary vascular cold sensor, as determined through TRPA1 pharmacological antagonism
or gene deletion. The initial cold-induced vasoconstriction is mediated via TRPA1-dependent
superoxide production that stimulates a2C-adrenoceptors and Rho-kinase-mediated MLC
phosphorylation, downstream of TRPA1 activation. The subsequent restorative blood flow
component is also dependent on TRPA1 activation being mediated by sensory nerve-derived
dilator neuropeptides CGRP and substance P, and also nNOS-derived NO. The results allow a
new understanding of the importance of TRPA1 in cold exposure and provide impetus for
further research into developing therapeutic agents aimed at the local protection of the skin in
disease and adverse climates.
DOI: 10.1038/ncomms6732 OPEN
1 BHF Cardiovascular Centre of Excellence and Centre of Integrative Biomedicine, Cardiovascular Division, King’s College London, London SE1 9NH, UK.
2Wolfson Centre for Age Related Diseases, King’s College London, London SE1 1UL, UK. Correspondence and requests for materials should be addressed to
S.D.B. (email: sue.brain@kcl.ac.uk).
NATURE COMMUNICATIONS | 5:5732 | DOI: 10.1038/ncomms6732 | www.nature.com/naturecommunications 1
& 2014 Macmillan Publishers Limited. All rights reserved.
M
echanisms involved in the vascular response to cold
have been under study for decades1. Local cold
exposure in mammals leads to an initial, rapid-onset
vasoconstriction that protects against heat loss and this is
followed by recovery, involving vasodilation, which is essential
to protect the area against local cold-induced injuries, such as
chilblains and susceptibility to frostbite1–3. Mammals respond to
cool temperatures with vasodilatation, which is associated with
rewarming and a healthy peripheral vasculature3. A loss of cold-
induced reflex recovery, associated with vasodilatation is a marker
of peripheral vascular disease or injury, leading to painful
conditions such as Raynaud’s disease4. Despite heavy debate, the
mechanisms behind the mammalian cold-induced reflex remain
unclear and the cutaneous thermosensitive components are
unknown. Studies have focused on sympathetic constrictor
mechanisms as a primary driver, with some evidence of sensory
nerve involvement5.
We hypothesized that the cold (o17 C) sensitive and non-
selective cation channel, transient receptor potential ankyrin-1
(TRPA1) channel6, may play a pivotal physiological role in cold-
induced vascular responses. The role of TRPA1 as a thermosensor
in vascular responses is unexplored, although it has been shown
to act as a cold sensor in Chinese Hamster Ovary cells in Ca2þ
imaging studies6 and be involved in mediating cold-induced
hyperalgesia in pathological states7–10. TRPA1 activation by a
range of exogenous and endogenous mediators can occur by
covalent activation of the cysteine residues localized to the amino
terminus11. There is little information on the endogenous role of
TRPA1 in cardiovascular regulation at present. Previous studies
have shown that TRPA1 agonists, either the exogenous vegetable-
derived agonist mustard-oil or the endogenous agonist
4-oxononenal (4-ONE), mediates cutaneous vasodilatation via
the activation of sensory nerves, but the physiological relevance of
this is unknown12–14. However, TRPA1-mediated constrictor
responses have not been observed. TRPA1 agonists mediate
dilation of peripheral resistance arteries in vitro, especially in
vessels, such as the cerebral vasculature15,16.
The goal of this study is to determine whether TRPA1 plays a
role as a vascular sensor of noxious cold, either initiating
responses or acting downstream of other cold-sensing proteins.
The experiments were designed using a novel murine in vivo
model of local acute environmental cold exposure in skin. To
achieve this, cutaneous blood flow was measured with a full-field
laser perfusion imager (FLPI) in vivo in genetically modified mice
and pharmacologically designed experiments. Ex vivo molecular
and biochemical techniques were used to delineate the role of
TRPA1.
Results
Local cold-induced vascular response is dependent on TRPA1.
The cold model was developed and characterized in male
anaesthetized wild-type (WT) mice (8–12 weeks). Following
baseline blood flow measurements, the ipsilateral hindpaw was
immersed in cold water (10 C for 5min), whilst the contralateral
paw remained untreated at room temperature. Exposure to
temperatures from 4 to 23 C (Supplementary Table 1) revealed
that the vasoconstriction response to 10 C exhibited substantial
TRPA1 dependency. Blood flow was then assessed immediately
following cooling, for 30min using FLPI, to allow dynamic
measurement, at a time period chosen to ensure the response to
cold exposure was complete (Fig. 1a). The maximum vasocon-
striction was observed at 0 to 2min following local cooling and
determined as the % maximum decrease in blood flow from the
precooling baseline (Fig. 1a–c and Supplementary Fig. 1). This
response was substantially less in TRPA1 knockout (KO) mice
and in WT mice pretreated with the TRPA1 antagonist
HC030031 (ref. 17) (Fig. 1c). It was not technically feasible to
measure blood flow with the FLPI during cold (10 C) water
immersion. However, an increased clearance, indicative of active
constriction, was measured by 99mTechnetium clearance during
cooling and this response was not observed in the presence of the
TRPA1 antagonist (Supplementary Fig. 2). WT and TRPA1 KO
mice have similar cardiovascular parameters at baseline
(Supplementary Fig. 3) and there was no significant change in
vascular responses to immersion in 26 C water (Supplementary
Table 1). Thus, TRPA1 mediates the initial vasoconstrictor
response of the local cold-induced vascular response. The
restorative response involves vascular relaxation, which follows
the constrictor phase and is measured as area under the curve
(AUC) (Fig. 1a,d and Supplementary Fig. 1). This response
involves blood flow recovery to baseline levels, referred to as the
‘restorative phase’ of the cold-induced vascular response.
There is debate and conflicting evidence concerning the relative
importance of TRPA1 as a primary cold sensor in cells and in vivo
models. TRPM8 (sensitive at temperatures o25 C (ref. 17))
rather than TRPA1 is considered to have a major role in
the response to deep body cooling18 and in cold-induced pain
behaviours19. Here the cold-induced vasoconstriction was partially
but significantly reduced in TRPM8 KO mice or in WT mice
pretreated with the TRPM8 antagonist AMTB compared with
control groups (Fig. 1e,f). AMTB pretreatment did not further
modify the cold-induced vascular response in TRPA1 KO mice
(Fig. 1h) and hence these results indicate that TRPM8 is involved,
but played a secondary role to TRPA1 in the cold-induced
vascular response in this study. Whilst the TRPA1 antagonist
HC030031 abolished vasodilation induced by the exogenous
TRPA1 agonist cinnamaldehyde in the mouse ear, AMTB had no
effect (Supplementary Fig. 4A–C), suggesting that the
pharmacological blockade of TRPM8 does not influence the
vascular effects of TRPA1 to other agonists. The results for the
restorative increased blood flow response following local cold
exposure (Fig. 1f,g,i) show a return to baseline levels in each case,
the magnitude of which correlates with that of the vasoconstrictor
response. TRPA1 is co-expressed in 60–75% of TRPV1-expressing
sensory C-fibre nerves6,20. However, neither pretreatment with the
TRPV1 antagonists SB366791, AMG9810 nor gene deletion of
TRPV1 altered cold-induced vascular responses (Supplementary
Table 2). Mice with TRPV4 gene deletion (a predicted warm
temperature sensor of 25–34 C) (refs 21,22) were similarly not
affected (Supplementary Table 2).
a2C-adrenoceptor and superoxide in cold treated hindpaws. To
investigate whether TRPA1 could stimulate the initial vasocon-
strictor phase via noradrenaline release from sympathetic nerves,
noradrenaline concentration was measured in cold-treated and
untreated-hindpaw tissue samples collected at the peak of the
cold-induced vasoconstriction. Tissue noradrenaline concentra-
tion was significantly decreased in the WT cold-treated hindpaw,
as assessed by enzyme linked immuno sorbent assay (ELISA).
This is possibly as a consequence of the intense vasoconstriction
and short half-life of noradrenaline. The noradrenaline con-
centrations were unchanged in the cold-treated hindpaw of
TRPA1 KO (Supplementary Fig. 5).
Furthermore, guanethidine-induced depletion of the peripheral
sympathetic nervous system or the pretreatment with the a-
adrenoceptor antagonist phentolamine caused a partial but
significant effect on the cold-induced vasoconstriction
(Fig. 2a,b). However, a2C-adrenoceptors have been shown to
influence cold-induced vascular responses23,24, and pretreatment
with the non-selective a2-adrenoceptor antagonist yohimbine or
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the selective a2C-adrenoceptor antagonist JP1302 also markedly
attenuated the initial cold-induced vasoconstriction phase
(Fig. 2c–f).
a2C-adrenoceptors are silent at 37 C, but in response to
cooling, their activity increases as a result of increased reactive
oxygen species generation25,26. Pretreatment with the highly
potent, cell-permeable superoxide dismutase (SOD) mimetic
TEMPOL also significantly reduced local cold-induced
vasoconstriction (Fig. 2g,h). To determine whether TRPA1
activation induced superoxide release, superoxide levels were
measured using the Lucigenin luminescence assay in hindpaw
skin tissues collected at the maximum vasoconstrictor phase. The
results showed a significant increase in the total superoxide
released in the cold-treated hindpaw compared with the
untreated or naı¨ve hindpaw at peak vasoconstriction following
local cold treatment in WT mice, with no significant changes in
WT mice pretreated with HC030031 (Fig. 2i) or TRPA1 KO mice
(Supplementary Fig. 6). By comparison, JP1302 had no effect on
superoxide generation (Fig. 2j). Thus, TRPA1 activation is linked
to superoxide generation and in turn, a2C-adrenoceptor
activation. The constrictor response to TRPA1 was significantly
inhibited by mito-TEMPO implicating mitochondria as the
possible source of superoxide generation (Fig. 2k).
The a2C-adrenoceptor mediated constriction is known to be
highly dependent on Rho-associated kinase (Rho-kinase) activ-
ity25. Pretreatment with the potent, cell-permeable and selective
Rho-kinase inhibitor Y27632 abolished the vasoconstrictor
component of the local cold-induced vascular response in WT
mice (Fig. 3a,b). The Rho-kinase-mediated myosin light chain
(MLC) activation signalling pathway is involved in mediating the
constriction of vascular smooth muscle cells27. Here there was a
significant increase in the phosphorylation of MLC protein at
Ser19 in hindpaw tissue samples at peak vasoconstriction
following local cold treatment compared with untreated control
tissues (Fig. 3c,d). This response was only observed in WT mice
and not TRPA1 KO mice, suggesting an important role of MLC
in regulating TRPA1-mediated responses induced by cold
treatment in the maximum vasoconstriction phase.
Restoration of blood flow post cold exposure requires TRPA1.
The initial TRPA1-dependent cold-induced vasoconstriction
directly precedes the recovery/restorative component (Fig. 1a,b),
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Figure 1 | Cold-induced vascular response is dependent on TRPA1. Blood
flow was measured using FLPI in anaesthetized mice following immersion of
the ipsilateral hindpaw in cold (10 C) water and contralateral paw
remained untreated. (a) Representative blood flow trace of a cold-induced
response in WT and TRPA1 KO mice. (b) Representative FLPI pictures
alongside grey/black ‘photo’ showing blood flow at baseline, 2 and 30min
in cold-treated hindpaw. (c) % Change in hindpaw blood flow from baseline
to 0–2min following cold treatment (maximum vasoconstriction) and
(d) Restoration of cutaneous blood flow, as assessed by AUC for 30min
following cold treatment in WT (n¼ 12) and TRPA1 KO (n¼9) or WTmice
pretreated with TRPA1 antagonist HC030031 (100mg kg 1, i.p., 30min,
n¼ 10) or control (10% DMSO in saline, i.p., 30min, n¼8) before cold
treatment. (e) % Maximum change in hindpaw blood flow from baseline to
0–2min following cold treatment (maximum vasoconstriction) in WT
(n¼ 10) and TRPM8 KO (n¼ 14) mice or WTmice pretreated with TRPM8
antagonist AMTB (10mg kg 1, i.p., 30min, n¼ 8) or control (10% DMSO
in saline, i.p., 30min, n¼ 10) before cold exposure. (f) Representative trace
of a cold-induced response in WT and TRPM8 KO mice. (g) Restoration of
cutaneous blood flow, assessed by AUC for 30min following cold treatment
in WT (n¼ 10) and TRPM8 KO (n¼ 14) mice or WTmice pretreated with
TRPM8 antagonist AMTB (10mg kg 1, i.p., 30min, n¼ 8) or control
(10% DMSO in saline, i.p., 30min, n¼ 10) before cold treatment. (h) %
Change in hindpaw blood flow from baseline to 0–2min following cold
treatment (maximum vasoconstriction) and (i) Restoration of cutaneous
blood flow, assessed by AUC for 30min following cold treatment in TRPA1
WT (n¼ 5) and KO (n¼ 5) pretreated with control (10% DMSO in saline,
i.p., 30min) or TRPA1 WT (n¼4) and KO (n¼4) pretreated with AMTB
(10mg kg 1, i.p., 30min). All error bars indicate s.e.m. *Po0.05,
**Po0.01, ***Po0.001 versus respective untreated, #Po0.05, ##Po0.01,
###Po0.001 versus cold-treated, $Po0.05 versus cold-treated TRPA1 WT
(analysis of variance, Bonferroni post hoc test).
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observed as a dilator response and analysed as AUC from the
maximum of the vasoconstriction phase until the end of the
measurement period (30min; Fig. 1d). A highly significant
restoration of blood flow was observed in control-treated groups,
but not in the absence of the initial constriction response to cold
(Fig. 1d). Therefore, neither WT mice treated with HC030031
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(intraperitoneally, i.p. 30min) before local cold treatment, nor
TRPA1 KO mice (Fig. 1d) exhibited this restorative vascular
relaxation. Indeed, as this restorative response was not observed
in the absence of cold-induced vasoconstriction, it was impossible
to assess from these experiments whether TRPA1 was involved in
the recovery/dilator component.
Thus, we questioned whether TRPA1 activity was required to
initiate the secondary restorative vasodilator phase by examining
WT mice treated with the TRPA1 antagonist HC030031
(intravenously, i.v.) during the vasoconstriction phase, following
local cold exposure. The results showed that HC030031,
administered only once the vasoconstriction had occurred,
prevented vasodilatation and as a consequence the return of
blood flow to baseline. However, the vasoconstrictor response
occurred normally in the respective control groups (Fig. 4a,b).
Hence, TRPA1 is pivotal in initiating the vasodilator response, in
addition to the vasoconstrictor response following cold exposure.
In support of this, chronic treatment with the ultra-potent
capsaicin analogue resiniferatoxin to remove the cutaneous
sensory nerve component had no effect on the constrictor
component (Fig. 4c,d), but significantly inhibited the dilator
component, implicating the involvement of sensory neurogenic
vasodilation (Fig. 4d,e and Supplementary Fig. 7). The role of
TRPA1 as an activator of the sensory neuronal vasodilator
axes was further implicated by the finding that pretreatment
with the CGRP receptor antagonist BIBN4096 only attenuated
the vasodilator component, whilst having no influence on the
constrictor component (Fig. 4f,h).
Neuropeptides and nitric oxide in the vasodilator component.
The localization of TRPA1 to sensory neurons expressing the
neuropeptide CGRP and substance P led us to investigate the
involvement of these vasodilators in the cold-induced vascular
response. It is known that TRPA1 agonist can mediate an increase
in cutaneous blood flow in vivo12,14. Pretreatment with the CGRP
receptor antagonists CGRP8–37 or BIBN4096 in WT mice caused
a significant loss of the cold-induced restorative response (Figs 4h
and 5a). A similar trend was observed in WT mice pretreated
with the substance P NK1 receptor antagonist SR140333
(Supplementary Fig. 8). Co-treatment with both CGRP8–37 and
SR140333 in WT mice did not further inhibit the cold-induced
vascular responses (Fig. 5b). Whilst a major involvement of the
neuropeptides is clear, the data suggest that other mechanisms are
also involved. The classic vasodilator prostaglandins are not
involved as the cyclooxygenase inhibitor indomethacin had no
effect (Supplementary Fig. 9). By comparison, pretreatment of
WT mice with the non-isoform selective nitric oxide synthase
(NOS) inhibitor L-NAME (LG-nitro-L-arginine methyl ester)
caused a significant decrease in the response (Supplementary
Fig. 10). Moreover, co-treatment with CGRP8–37, SR140333 and
L-NAME abolished the cold-induced vascular response (Fig. 5b).
Whilst a selective endothelial NOS inhibitor is unavailable,
pretreatment with the selective neuronal NOS inhibitor,
S-methyl-L-thiocitrulline (SMTC) alone inhibited the cold-
induced vascular response (Supplementary Fig. 11) and in
combination with the neuropeptide receptor antagonists, the
response was substantially attenuated (Fig. 5c). These data
highlight that the combined role of vasodilating sensory
neuropeptides and NO mediates the recovery of normal blood
flow following the initial constrictor response to local cooling.
Discussion
This study provides evidence that TRPA1 is an essential vascular
sensor of cold, playing a primary role in the vascular response to
noxious cooling. Development of a murine model of local cooling,
which simulates exposure and recovery to local cold and can be
modified by pharmacological and genetic means, provides a new
insight into the mechanisms underlying cold-induced vascular
responses, first discovered in 1930 (ref. 1). The major novel
findings are: (1) TRPA1 acts as a vascular cold sensor to ‘kick
start’ the protective cold-induced vascular response as the
constrictor response is not observed in the presence of TRPA1
antagonists or in TRPA1 KO mice (2) the initial TRPA1-
dependent cold-induced vasoconstriction involves TRPM8 and is
mediated via stimulation of a2C-adrenoceptors following
superoxide generation and involving Rho-kinase-mediated MLC
phosphorylation downstream of TRPA1 activation and (3) the
TRPA1-mediated cold-induced restorative vasodilator
component of the reflex is mediated by the sensory nerve-
derived neuropeptides CGRP and substance P, and nNOS-
derived NO following TRPA1 activation.
Physiological human studies have described cold pain percep-
tion at low temperatures (o15 C) (ref. 28). In this study, we
established a novel acute cold exposure model to enable the
quantitative measurement of vascular responses following the
local cooling of the hindpaw of anaesthetised mice. Local cold air
exposure (28 to 5 C) has been previously demonstrated to reduce
blood flow and skin temperature of mouse hindpaw, with
reproducible results derived at 10 C (ref. 24). Here immediately
after local cold water immersion (10 C for 5min), a decrease in
Figure 2 | Sympathetic nerves, a2C-adrenoceptors and superoxide in cold-induced vasoconstriction. Blood flow was measured using FLPI in
anaesthetized mice following immersion of the ipsilateral hindpaw in cold (10 C) water and the contralateral hindpaw remained untreated. (a) %
Maximum change in hindpaw blood flow from baseline to 0–2min following cold treatment (maximum vasoconstriction) in WTmice pretreated with
guanethidine (30mg kg 1, s.c., 4 days, n¼ 7) or control (saline, s.c., 4 days, n¼ 7) and (b) WTmice pretreated with the a-adrenoceptor antagonist
phentolamine (10mg kg 1, i.v., n¼ 6) or control (saline, i.v., n¼ 6). (c) Representative trace of a cold-induced response and (d) % Change in hindpaw
blood flow from baseline to 0–2min following cold treatment (maximum vasoconstriction) in WTmice treated with the a2-adrenoceptor antagonist
yohimbine (10mg kg 1, s.c., 30min, n¼ 5) or control (saline, s.c., 30min, n¼ 5). (e) Representative trace of a cold-induced response and (f) % Change in
hindpaw blood flow from baseline to 0–2min following cold treatment (maximum vasoconstriction) in WT mice treated with the a2C-adrenoceptor
antagonist JP1302 (3 mg kg 1, s.c., 60min, n¼6) or control (saline, s.c., 60min, n¼ 6). (g) Representative blood flow trace of a cold-induced response and
(h) % Change in blood flow from baseline to 0–2min following cold treatment (maximum vasoconstriction) in WTmice treated with the SOD mimetic
TEMPOL (30mg kg 1, i.v., 5min, n¼4) or control (saline, i.v., 5min, n¼4). Superoxide levels were measured at 2min (maximum vasoconstriction)
following cold treatment in the hindpaw tissue samples by lucigenin chemiluminescence in (i) naı¨ve, WTmice pretreated with TRPA1 antagonist HC030031
(100mg kg 1, i.p., 30min) or control (10% DMSO in saline, i.p., 30min, n¼4–5) and (j) WTmice pretreated with JP1302 (3 mg kg 1, s.c., 60min) or
control (saline, s.c., 30min, n¼6–8). (k) % Change in blood flow from baseline to 0–2min following cold treatment (maximum vasoconstriction) in WT
mice treated with the mitochondria-targeted superoxide scavenger mito-TEMPO (10mg kg 1, i.p., 60min, n¼ 9) or control (saline, i.p., 60min, n¼8). All
error bars indicate s.e.m. *Po0.05, **Po0.01,***Po0.001 versus respective untreated, #Po0.05, ##Po0.01 versus cold-treated hindpaw (analysis of
variance, Bonferroni post hoc test).
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blood flow was observed, followed by a gradual increase in blood
flow to restore blood flow to baseline levels, with minimal reflex
changes in the untreated hindpaw. The cold-induced vascular
response observed in this study did not involve the previously
reported Hunting reaction in cold-induced vasodilatation, which
is characterized by cyclic oscillations in blood flow induced by
subsequent vasoconstrictions and vasodilatations in extremities
measured during the active cooling phase1,3. We were unable to
image blood flow during the actual cooling phase, although we
determined a significant vasoconstriction during this phase,
through use of a 99mTc clearance technique. It is known that
excessive vasoconstriction and/or lack of vasodilatation in
response to cold or in Raynaud’s disease causes tissue hypoxia,
and in extreme cold conditions, this can result in cyanosis4. Thus,
there is an urgent need to fully understand the mechanisms
involved.
TRPA1 deletion did not change systemic blood pressure and
heart rate, highlighting that TRPA1 does not play a role in
regulating baseline blood pressure, although TRPA1 may be
involved in cardiovascular autonomic reflexes associated with
vasovagal reflexes13. Furthermore, TRPA1 antagonists have no
effects in altering core body temperature in mice29 nor does
TRPA1 act as a thermoregulator30. TRPA1 was initially reported
as a cold sensor when Story et al.6 demonstrated that cold
temperatures (o17 C) induced Ca2þ influx in TRPA1
expressing-Chinese Hamster Ovary cells using Ca2þ imaging
studies. Later, Andersson et al.31 showed an increase in paw
withdrawal latencies in TRPA1 KO mice when placed on a cold
plate at 10 C. The current study was carried out using the same
strain of mice. The cold reflex comprising of vasoconstriction
followed by restoration of blood flow to baseline levels, (increased
blood flow) after exposure of the ipsilateral hind paw to
environmental cooling (10 C for 5min) was substantially
reduced in TRPA1 KO mice and in WT mice pretreated with
the TRPA1 antagonist HC030031. The local nature of the
response was confirmed by the finding that blood flow remained
relatively stable in the untreated contralateral paw, irrespective of
treatment. This provided clear evidence that TRPA1 plays a
primary role as a vascular cold sensor.
The role of TRPA1 as a noxious cold pain sensor has been a
controversial issue. Studies involving TRPA1 KO mice have
yielded conflicting results, where (1) Bautista et al.32 showed no
change in cold-induced nociceptive responses ( 10 to  20 C),
(2) Kwan et al.33 demonstrated a decrease in cold (0 C)-induced
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pain sensitivity in vivo and (3) there were cold-sensing deficits
following prolonged cold exposure in vitro (13 C) and in cold
(0 C) plate test in vivo9. These differences may arise due to the
different methodologies used and temperatures studied. However,
our present finding that TRPA1 initiates the cold-induced
vascular response means that it is possible that changes in
blood flow could have influenced the various recordings made
and thus contribute to the lack of reproducible findings.
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Thermosensitive TRPM8 (o25 C) is expressed on sensory
neurons and mediates the response to deep body cooling which is
associated with cutaneous vasoconstriction18. TRPM8 is
considered to be implicated in thermoregulation as TRPM8
antagonists caused a change in core body temperature in
conscious mice and rats18. In addition, TRPM8 was shown to
override TRPA1 in cold (5–30 C) detection in neural and
behavioral studies in vivo34, suggesting that TRPM8 rather than
TRPA1 is required for acute cold pain sensing in mammals. In
our studies, pharmacological blockade or genetic deletion of
TRPM8 caused a significant loss of the cold-induced vascular
responses, but to a lesser extent than the pharmacological
blockade or genetic deletion of TRPA1. Moreover, a TRPM8
antagonist did not further modify the vascular response in
TRPA1 KO mice in our model. This finding provides
confirmation that TRPA1 is the primary vascular cold sensor in
this model, overriding TRPM8 activity and contrasts with
evidence that the selective ablation of TRPM8 neurons in vivo
induced a loss of nociceptor sensitivity to both innocuous (17 C)
and noxious (0 C) cold19.
Our findings illustrate a prominent role of TRPA1 in mediating
the cold-induced vascular response, whereas a major involvement
of sympathetic nerves in mediating cold-induced vasoconstriction
is widely accepted35. Indeed, sensory and sympathetic nerves have
a close overlapping distribution pattern around blood vessels in
the periphery and a reciprocal trophic influence was observed
following the denervation of either the sensory peptide- or
catecholamine-containing sympathetic nerves36. Whilst the
pharmacological depletion of sympathetic nerves using
guanethidine24 or blockade of a-adrenoceptors using phentol-
amine had a partial inhibitory effect on the total cold-induced
vasoconstriction, we observed a decrease in total noradrenaline
concentrations in the cold-treated hindpaw at maximum
vasoconstriction in TRPA1 WT but not KO mice, compared to
untreated samples. This finding is in agreement with previous
studies in plasma from human cold (5 C) studies37 and in
cutaneous dog veins (37–28 C) (ref. 38). The observed changes in
noradrenaline concentrations in the paw were TRPA1-dependent,
implying an involvement of sympathetic nerves.
Superficial cutaneous vessels exhibit increased responsiveness
during cooling35,39 and it is established that a1- and a2-
adrenoceptors mediate peripheral vasoconstriction. All the
adrenergic antagonists that we tested exhibited significant
effects on the local cold-induced vasoconstriction including the
selective a2-adrenoceptors antagonist yohimbine, in agreement
with previous findings in humans40. Different subtypes of a2-
adrenoceptors are localized in small veins and arteries41 and cold
treatment has previously been shown to amplify a2C-
adrenoceptors in isolated mouse tail arteries in vitro23. We
demonstrated that the pharmacological antagonism of a2C-
adrenoceptors using JP1302 caused a significant decrease in the
local cold-induced vasoconstriction.
a2C-adrenoceptors are normally silent at thermoneutral
temperatures (37 C), but following cooling (28 C), they are
distributed to the plasma membrane42. Although the mechanisms
underlying this phenomenon are unclear, both reactive oxygen
species and Rho-kinase have been suggested to be involved25 and
this was directly investigated in vivo during this study. We
showed that pretreatment with the SOD mimetic TEMPOL
caused a significant decrease in cold-induced vasoconstriction in
WT mice, highlighting that TEMPOL may reduce the
accumulation of superoxide to water and oxygen in the cold-
treated hindpaw, consistent with previous in vitro findings
involving the tail artery26. We further measured the levels of
superoxide in hindpaw tissue samples at the maximum
vasoconstriction phase and provided novel evidence showing
that cooling induced an increase in total superoxide levels in the
cold-treated hindpaw in a TRPA1-dependent manner. This is the
first study to highlight an association between TRPA1 activation
and superoxide generation following local cooling treatment
in vivo. We propose that superoxide is produced downstream of
TRPA1 activation by cold exposure in the peripheral vasculature
and upstream of a2C-adrenoceptor activity, as the a2C-
adrenoceptor antagonist JP1302 was able to block constriction,
but not superoxide production. Of note, mito-TEMPO inhibited
the vasoconstriction, providing evidence that the mitochondria
are the cellular source.
Superoxide has been suggested to cause vasoconstriction
through the Rho-kinase/ROCK-mediated pathways in the
vascular smooth muscle cells25,26. Rho-kinase can also be
stimulated by noradrenaline and/or superoxide in response to
localized cooling26. We investigated the role of the Rho-kinase-
mediated pathways in our cold model. WT mice were pretreated
with the selective cell-permeable Rho-kinase inhibitor Y27632,
which was previously shown to have no modulatory effects on a2-
adrenoceptors in vitro in control experiments (37 C) (ref. 25).
Pretreatment with Y27632 completely abolished the cold-induced
vasoconstriction at 10 C, in agreement with previous in vitro
cooling (28 C) studies in mouse tail artery using pressure
myography25. Hence, our results support previous ex vivo
findings and provide new evidence demonstrating that cold-
induced vasoconstriction at a lower temperature (10 C) is
dependent on the generation of superoxide following activation
of TRPA1, which further leads to activation of Rho-kinase and
translocation of a2C-adrenoceptors to the cell surface membrane
for activation in the mouse hindpaws.
Rho-kinase can modulate smooth muscle contraction via an
increase in MLC activity27. Stimulation of postsynaptic
a2-adrenoceptors using a selective a2-agonist, UK14304 was
previously shown to increase vascular tone via an increase in
[Ca2þ ]i and MLC phosphorylation in spiral strips of rabbit
saphenous vein in vitro43. We hypothesized that there was an
increase in MLC phosphorylation in the local cold-induced vaso-
constriction phase. Indeed, we provide evidence demonstrating
Figure 4 | TRPA1 mediates the vasodilator component of cold-induced responses. Blood flow was measured using FLPI in anaesthetized mice following
immersion of the ipsilateral hindpaw in cold (10 C) water and the contralateral hindpaw remained untreated. (a) Representative blood flow trace of a
cold-induced vascular response and (b) restoration of cutaneous blood flow, as assessed by AUC for 30min following cold water immersion in WTmice
pretreated with the TRPA1 antagonist HC030031 (6mg kg 1, i.v., n¼ 6) or control (8% DMSO in 2% Tween-80 in saline, n¼ 6) at the maximum
vasoconstriction phase following local cold water immersion. (c) % Maximum change in hindpaw blood flow from baseline to 0–2min following local cold
treatment (maximum vasoconstriction), (d) Representative blood flow trace of a cold-induced vascular response and (e) Restoration of cutaneous blood
flow, as assessed by AUC for 30min following cold water immersion in WTmice pretreated with the TRPV1 agonist resiniferatoxin (0.3mg kg 1, s.c. daily.,
4 days, n¼ 8) or control (10% ethanol, 10% Tween-80 in saline, s.c. daily, 4 days, n¼9). (f) Representative blood flow trace of a cold-induced vascular
response, (g) % Maximum change in hindpaw blood flow from baseline to 0–2min following local cold treatment (maximum vasoconstriction) and
(h) Restoration of cutaneous blood flow, as assessed by AUC for 30min following cold water immersion in WTmice pretreated with the CGRP receptor
antagonist BIBN4096 (0.3mg kg 1, i.v., 5min, n¼9) or control (saline, i.v., 5min, n¼ 10). All error bars indicate s.e.m. *Po0.05, **Po0.01, ***Po0.001
versus respective untreated, ##Po0.01, ###Po0.001 versus cold-treated hindpaw (analysis of variance, Bonferroni post hoc test).
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that there was an increase in phosphorylated MLC protein in
cold-treated hindpaw tissue samples at the maximum
vasoconstriction phase of TRPA1 WT but not KO mice.
Cumulatively, these findings provide a novel mechanism
proposing that local cold exposure activates TRPA1, which
causes an increase in superoxide generation, activating
Rho-kinase to phosphorylate MLC and/or translocate
a2C-adrenoceptors, ultimately leading to vasoconstriction in the
mouse hindpaw.
The role of TRPA1 in mediating vasorelaxant effects is well
documented in the literature12,13,15, with little evidence of the
vascular constrictor activity. Hence, we further determined if
endogenous TRPA1 activation was responsible for initiating the
restorative phase that follows the constrictor activity in this cold
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cold-induced vascular response in WTmice. (b) Cold-induced vascular response in WTmice pretreated with a combination of CGRP8–37 and NK1 receptor
antagonist SR140333 (480nmol kg 1, n¼ 8) with or without the non-selective NOS inhibitor L-NAME (15mg kg 1, n¼ 7) and control (0.01% BSA in
saline, n¼ 10). (c) Effects of CGRP8–37, SR140333 and the selective nNOS inhibitor SMTC (10mg kg 1, n¼6) or control (0.01% BSA in saline, n¼ 7) on
the cold-induced vascular response in WT mice. All error bars indicate s.e.m. *Po0.05, ***Po0.001, ****Po0.0001 versus respective untreated,
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 ) generation) that can also activate the ROCK-mediated pathways and increase constriction via
phosphorylated MLC-induced increase in [Ca2þ ]i. The O2 induces the translocation of a2C-adrenoceptors from the Golgi to the surface membrane and
increases adrenergic activity in the VSMC in a ROCK-dependent fashion25. (2) The restoration of blood flow following local cold treatment is essential in
restoring blood flow to baseline to protect against local cold-induced injuries. This phase is mediated by the release of CGRP, substance P and nitric oxide
following TRPA1 activation of sensory neurons. MLC-P, myosin light chain phosphatase; NA, noradrenaline; p-MLC; phosphorylated myosin light chain;
VSMC, vascular smooth muscle cell.
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model. To determine this, we treated WT mice with HC030031
(i.v.) during the vasoconstriction phase following local cold water
immersion. The results showed that although the constrictor
phase was able to proceed normally following cold exposure, the
acute treatment with the TRPA1 antagonist (i.v.) prevented the
vasodilator/recovery phase.
TRPA1 is expressed on sensory neurons and cold-induced
responses are known to be controlled neurally1,5,44, with
conflicting evidence of mechanisms in the literature3. Since
TRPA1 is co-expressed in TRPV1-positive sensory neurons6,20,
possible interactions between the two channels may occur. We
show that neither pharmacological blockade with two TRPV1
antagonists, nor TRPV1 deletion influenced the cold-induced
response. TRPV4 has been suggested to act as an environmental
cutaneous thermosensor21, but TRPV4 deletion did not affect the
response, consistent with the knowledge that there was no change
in core body temperature between TRPV4 WT and KO mice
following a cold stress (4 C for 150min)45.
On the other hand, the link between TRPA1 and the major
sensory neuropeptide dilator CGRP is clear. Our studies using the
non-peptide selective antagonist BIBN4096 showed that only the
restorative vasodilation phase was affected, which is important in
protecting against local cold-induced injury but not the initial
constriction component. The pharmacological blockade of either
CGRP receptors or the substance P NK1 receptors caused a
significant reduction in the cold-induced restorative response,
indicating a key involvement of sensory nerves in this model. A
finding was supported here by sensory nerve depletion studies
with resiniferatoxin. Whilst we gained no evidence for a role for
vasodilator prostaglandins, pretreatment with L-NAME signifi-
cantly reduced the cold-induced residual vasodilator response, as
was observed in previous cooling (4 C) studies in human skin46.
A selective endothelial NOS isoform inhibitor is unavailable, but
we show that nNOS-derived NO is involved in mediating the
restorative vasodilator response following local skin cold
treatment at 10 C, using the selective nNOS inhibitor SMTC47.
This is the first study establishing a link between nNOS-derived
NO and TRPA1 in mediating vasodilator responses. The
pretreatment of mice with a combination of the neuropeptide
receptor antagonists and SMTC or L-NAME was able to
substantially block the cold-induced blood flow responses, with
no significant change in the untreated hindpaw. Thus, there is a
clear involvement of the vasodilator sensory neuropeptides and
NO in the cold-induced restorative component. The importance
of sensory neurogenic vasodilator responses is unclear; here we
provide evidence for their functional importance in restoring
cutaneous baseline blood flow to its healthy level, rather
than acting in a capacity that leads to obvious increased net
blood flow over baseline. This is indicative of a physio-
logically important role, allowing the restoration of a healthy
skin flow, necessary to protect the skin against cold-induced
injury. CGRP has been shown to tonically cross-inhibit cold-
sensitive spinal neurons48. We did not observe this in terms of
blood flow, just that the normal ability to return to basal blood
flow was lost in the absence of functioning neurogenic
vasodilation. Whilst the stimulation of sensory nerves with
either exogenous TRPA1 or TRPV1 agonists is known to lead to
neurogenic vasodilation, the importance of this TRPA1-mediated
role of sensory neurogenic vasodilatation in restoring a healthy
baseline blood flow to skin has not been defined before. This
should be considered as distinct from the increased blood flow
commonly observed in response to stimulation of sensory nerves
by TRPV1 (for example, flushing in response to the TRPV1
agonist capsaicin).
Collectively, this novel evidence highlights the important role
of TRPA1 in (1) sensing the change in temperature at 10 C,
(2) inducing the initial vasoconstriction phase and (3) stimulating
the release of sensory nerve-derived neuropeptides and NO,
which are essential in replenishing the blood flow that acts to
protect against local cold-induced injury (Fig. 5d). To conclude,
we have revealed a primary role of the TRPA1 in orchestrating
the vascular response to local cold exposure. This finding is
consistent with TRPA1 playing a primary physiological role, as a
vascular sensor for noxious cold and that as a consequence is also
important for the pathophysiological understanding of peripheral
cold injury and disease. The results introduce a new paradigm
whereby TRPA1 is an important activation step, acting in two
distinct ways to affect the successful vascular protective response
to local noxious cold exposure.
Methods
Animals. Male mice (8–12 weeks of age) were used in all experiments. The initial
characterization of cold-induced vascular responses was performed in CD1 mice,
purchased from Charles River (Kent, UK). TRPA1 KO mice (C57BL/6-B6129P1/
F2J mixed genetic background) and WT littermates were bred from heterozygotic
mice kindly provided by Drs Kelvin Kwan (Harvard Medical School, Boston, MA)
and David Corey (Harvard Medical School, Boston, MA)33. TRPM8 KO49, TRPV1
KO50 and TRPV4 KO45 were raised on a C57/BL6 background and their WT
littermates were used as controls. All genetically modified mice were backcrossed
for at least eight generations into their respective background. Mice were housed in
a climatically controlled environment, on a 12-h light/dark cycle, with free access to
water and standard food ad libitum. All experiments were conducted in accordance
with the UK Home Office Animals (Scientific Procedures) Act, 1986 and were
approved by the King’s College London Animal Care and Ethics Committee. All
experiments were conducted in a blinded manner. Animals were randomly
assigned to control or treatment groups and the experimenter was blinded towards
the genetic background of animals at the time of experiment.
Cutaneous blood flow by full-field laser perfusion imager. Mice were
anaesthetized i.p. with ketamine (75mg kg 1) and medetomidine (1mg kg 1) and
cutaneous blood flow was assessed in the whole plantar hindpaw area using the
Full-Field Laser Perfusion Imager (FLPI, Moor Instruments, UK)12,14. The
environmental cooling model consisted of recording baseline blood flow in both
hindpaws to ensure the haemodynamic vascular responses have stabilized
following anaesthesia. The ipsilateral hindpaw was subsequently exposed up to the
level of the joint between the tibia and the calcaneum to cold water (10 C for
5min). The contralateral paw was untreated at room temperature (19–21 C) and
served as a control. Changes in blood flow after these treatments were followed
for 30min. Mice were placed on a heating mat, in the ventral position
maintained at 36 C for blood flow measurements. The response to cooling
consisted of an initial reduced flux, in keeping with vasoconstriction, followed by a
slow developing sustained increased flux, consistent with vasodilatation. Water
is a much more efficient medium at cooling down tissues and this model
allowed blood flow responses to be monitored following the local cooling
treatment. Results are expressed as (1) a measure of maximum % decrease in blood
flow from baseline to 0–2min following cold treatment or (2) arbitrary flux units
( 103 flux units) measured as area under the recorded flux (response curve)
versus time for the entire recording period for 30min following cold treatment
(Supplementary Fig. 1).
Cutaneous blood flow in the ear by laser Doppler techniques. Skin blood flow
was measured concomitantly in both ears of mice anaesthetized with ketamine
(75mg kg 1) and medetomidine (1mg kg 1) using laser Doppler flowmeter
(Moor instruments, UK) and a PowerLab data acquisition system (AD instruments,
UK) or Full-Field Laser Perfusion Imager (FLPI)13. A probe, allowing blood flow to
be measured precisely at one point in the ear (1mm2 and to 1–2mm depth), was
placed at one point of each ear and a baseline reading was obtained for 2–5min.
Cinnamaldehyde (20 ml, 10%) or capsaicin (200 mg solution) was topically applied
to the ipsilateral ear and vehicle; 10% dimethylsulphoxide (DMSO) in ethanol or
100% ethanol, respectively, on the contralateral ear. Blood flow was subsequently
measured for 30min (cinnamaldehyde studies) or 20min (capsaicin studies), and
data collected as flux units that are proportional to blood flow. All experiments
using cinnamaldehyde administration was conducted using the laser Doppler
flowmeter and in some experiments, images were captured using FLPI, whilst all
experiments using capsaicin were conducted using the FLPI. The typical response
to cinnamaldehyde or capsaicin involves an initial gradual increase in blood flow
from baseline, as a result of vasodilatation. Blood flow data were expressed as area
under the recorded flux versus time trace for the entire recording period (30min)
following topical treatment.
Changes in blood flow by 99mTc clearance technique. Blood flow was assessed
using a clearance technique in paw tissues51. Test agents containing an equal
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amount of radioactive 99mtechnetium (99mTc) were prepared immediately before
use. Mice were pretreated with control (10% DMSO in saline, i.p., 30min) or
TRPA1 antagonist HC030031 (100mg kg 1, i.p., 30min), anaesthetized with
ketamine (75mg kg 1) and medetomidine (1mg kg 1) and saline was co-injected
with an equal amount of radioactive 99mTc (20kBq per site, intradermally (i.d.)
30ml; Nuclear Medicine, Guy’s Hospital, London) in the plantar skin of WT mice.
An equal amount of salineþ 99mTc was used as a measurement of total
radioactivity. Following i.d. injection, the ipsilateral hindpaw was immersed in local
cold water (10 C) for 5min and the contralateral paw remained untreated. At 0–
2min following local cold exposure, the clearance period was terminated by
cervical dislocation and death, which reduce blood flow to zero. The paw tissues
were rapidly collected and the remaining radioactivity was immediately counted in
an adjacent radioactive gamma counter. Clearance was calculated by comparison of
the paw tissue and total radioactivity readings. Local cold treatment-specific
clearance in the ipsilateral paw was then calculated by comparison with the
untreated contralateral paw, normalized to 100% and expressed as a % change in
clearance compared to the untreated paw. Positive values are due to decreased
clearance, which is directly related to decrease blood flow and vasoconstrictor
activity.
Radiotelemetry. Blood pressure and heart rate were measured using a
radiotelemetry device (PA-C10, DSI, NL), with the catheter placed in the left
carotid artery and advanced towards the aortic arch52. It was secured using surgical
braided silk (5.0, waxed, Pearsalls sutures) and the outer wound was closed
with absorbable sutures (4.0, Ethicon, Johnson and Johnson) in a discontinuous
pattern. The transmitter was placed subcutaneously in the left flank and the
transmitter pocket was irrigated with sterile saline. All procedures were conducted
using aseptic techniques under isoflurane anaesthesia (2.5%, Abbott Laboratories,
UK) in 3 lmin 1 O2. Surgical anaesthesia was assessed by loss of the paw
pinch reflex. Buprenorphine was administered intramuscularly (50 mg kg 1,
Vetergesic, Alstoe Animal Health) for pain relief. All animals were housed singly
and allowed to recover for 7 days before recording baseline blood pressure for
three continuous days in a quiet room. Data were collected and calculated by the
DSI software (DSI Dataquest A.R.T.) and analysed in Microsoft Excel and
GraphPad Prism 5.
Antagonists and inhibitors. The TRPA1 antagonist HC030031 (2-(1,3-dimethyl-
2,6-dioxo-1,2,3,6-tetrahydro-purin-7-yl)-N-(4-isopropyl-phenyl)-acetamide 1)
(Tocris, UK) was either dissolved in 10% DMSO in saline and administered i.p. at a
dose of 100mg kg 1 30min53 before local cold water immersion or in 8% DMSO,
2% Tween-80 in saline and administered i.v. at a dose of 6mg kg 1 (ref. 54) at the
peak vasoconstriction phase (0–2min) following local cold water immersion. The
TRPM8 antagonist AMTB (N-(3-aminopropyl)-2-[(3-methylphenyl) methyl]oxy-
N-(2-thienylmethyl)benzamide hydrochloride salt) was dissolved in 10% DMSO in
saline, TRPV1 antagonist SB366791 (40-Chloro-3-methoxycinnamanilide) in 2%
DMSO in saline or AMG9810 ((2E)-N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-3-
[4-(1,1-dimethylethyl)phenyl]-2-propenamide) (Sigma, UK) in 2% DMSO and 5%
Tween-80 in saline and administered at a dose of 10 (ref. 55), 25 (ref. 56) and
50mg kg 1 (ref. 57), respectively. The CGRP receptor antagonists were dissolved
as follows: CGRP8–37 was dissolved in 0.01% bovine serum albumin (BSA)
and administered i.v. at 400 nmol kg 1 (ref. 58) (Tocris,UK). BIBN4096
((1-piperidinecarboxamide,N-[2-[[5-amino-1-[[4-(4-pyridinyl)-1-piperazinyl]
carbonyl]pentyl]amino]-1-[3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-
(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-,[R-(R*,S*)]) (Tocris, UK) was dissolved
in a minimum volume of 1M HCl (0.5mg per 50 ml) and the solution was made up
to the required final volume with saline at a final stock concentration of
2mgml 1, and then titrated with 1M NaOH to return the pH to neutral.
BIBN4096 was administered i.v. at 0.3mg kg 1 (refs 59,60). The NK1 receptor
antagonist SR140333 ((S)1-(2-[3-(3,4-dichlorophnyl)-1-(3-isopropoxyphenyl-
acetyl)piperidin-3-yl]ethyl)-4-phenyl-1-azoniabicyclo[2.2.2]octane chloride)60, a
gift from Dr X. Emonds-Alt, Sanofi, Toulouse, France, was dissolved in saline and
administered at a dose of 480 nmol kg 1 i.v. The non-selective NOS inhibitor
L-NAME60 or the selective nNOS inhibitor SMTC (Sigma, UK) was dissolved in
saline and administered i.v. at 15mg kg 1 (ref. 61). The cyclooxygenase inhibitor
indomethacin (Sigma, UK) was dissolved in 5% NaHCO3 in saline and
administered i.v. at 20mg kg 1 (ref. 60). The non-selective a-adrenoceptor
antagonist phentolamine62 was dissolved in saline and administered i.v. at a dose of
10mg kg 1, whilst the sympathetic nerve blocker guanethidine63 (Sigma, UK) was
dissolved in saline and administered subcutaneously (s.c.), at a dose of 30mg kg 1
daily for four consecutive days. The a2-adrenoceptor antagonist yohimbine
hydrochloride, the selective a2C-adrenoceptor antagonist JP1302 dihydrochloride
and the selective Rho-associated protein kinase (ROCK) inhibitor Y27632 (Tocris,
UK) were dissolved in saline and administered at a dose of 10mg kg 1 (i.p.)64,
3 mg kg 1 (s.c.)65 or 5mg kg 1 (i.p.)66, respectively. The SOD mimetic TEMPOL
was dissolved in saline and administered i.v. at a dose of 30mg kg 1 (ref. 60),
whilst the mitochondria-targeted superoxide scavenger mito-TEMPO was
dissolved in saline and administered i.p. at a dose of 10mg kg 1 (ref. 67). The
capsaicin analogue resiniferatoxin was dissolved in 10% ethanol, 10% Tween-80 in
saline and administered s.c. at a dose of 0.3mg kg 1 for three consecutive days68.
These drugs were administered i.v. 5min, i.p. 30min and s.c. 60min before
baseline blood flow recording. The doses used were based on previous and
preliminary studies.
Superoxide measurements. Superoxide release from fresh plantar hindpaw skin
samples was measured by chemiluminescence using lucigenin (bis-N-methylacri-
dinium nitrate; Sigma Aldrich) as a probe. Chemiluminescense was measured using
a GloMax 20/20 luminometer (Promega, UK). Skin samples were collected 0–2min
post cold water immersion, which corresponds to the peak vasoconstriction phase
of the cold-induced vascular response, as determined by laser speckle imaging
studies. The samples were placed in 100ml of modified Krebs’ buffer (composition
of 131mM NaCl, 5.6mM KCl, 25mM NaHCO3, 1mM NaH2PO4 H2O, 5mM
glucose, 5mM HEPES, 100 mM L-arginine, 2.5mM CaCl2, 1mM MgCl2 and
100 mM NADPH, pH7.4) and a further 100 ml of modified Krebs’ buffer containing
lucigenin (10mM) and NADPH (500 mM) was added to each sample with or
without SOD (50Uml 1). Chemiluminescense was recorded after 4min. Results
are expressed as the difference in the relative light units per mg of protein in the
presence and absence of SOD after subtraction of background luminescence69.
Western blotting. Plantar hindpaw skin tissues of TRPA1 WT and KO mice were
collected 0–2min post cold water immersion and snap frozen at  80 C until
processing. Tissue was then lysed using in SDS lysis buffer containing protease (one
tablet per 50ml, Roche, Germany) and phosphatase (one tablet per ml, Roche,
Germany) inhibitor. Lysates were clarified by centrifuging at 2,600 g for 10min at
4 C. Protein concentration was assessed using the Bradford dye-binding method
kit (Bio-rad). Protein (30 mg) was loaded and separated by SDS–polyacrylamide gel
electrophoresis and transferred to polyvinylidene difluoride membranes using a
semi-dry technique. Membranes were blocked with 5% BSA in Tris-buffered saline
(TBS) and 0.1% Tween and incubated with primary antibodies against MLC-2 (t-
MLC, 1:500 dilution, Cell Signaling, UK, #3672) and phospho-MLC (Ser19, 1:500
dilution, Cell Signaling, UK, #3671) in 5% BSA in TBS and 0.1% Tween for 16 h at
4 C. Membranes were washed further with TBS 0.1% Tween and incubated with a
horseradish peroxidase conjugated anti-rabbit secondary antibody (1:2,000 dilu-
tion, Sigma, UK, #AP132P). Proteins were detected by enhanced chemilumines-
cence (ECL, Piercenet, UK) and developed using the Syngene gel doc dark room
system (Chicago, USA). Densitometric analysis performed using Image J analysis
software (NIH, USA). MLC phosphorylation was assessed by calculating the ratio
of anti-phosphorylated-MLC signal to anti-total MLC signal with defined regions,
normalized to the loading control b-actin (1:2,000 dilution, Sigma, UK, #A1978).
Uncropped images of immunoblots are shown in Supplementary Fig. 12.
Quantification of noradrenaline using ELISA. Noradrenaline levels were mea-
sured using a commercially available Noradrenaline Enzyme Linked Immuno
Sorbent Assay (ELISA) kit (RE59261; IBL International, Hamburg, Germany) in
hindpaw tissue homogenates of WT and TRPA1 KO mice following cold treatment
at 0–2min. Samples were collected in a sterile environment and snapfrozen at
 80 C until processing. Tissue samples were homogenized in RIPA lysis buffer
(Sigma, UK) containing protease inhibitors (one tablet per 50ml, Roche, Germany)
and lysates were clarified by centrifuging at 2,600 g for 10min at 4 C. According to
the manufacturer’s instructions, 20 ml of tissue lysates, standards and controls were
added to extraction plates. After extraction, bound noradrenaline (25 ml) was eluted
using release buffer and transferred to a 96-well ELISA plate. Noradrenaline
antiserum (50 ml) was incubated with all samples at room temperature for 120min
on an orbital shaker; the plates were thoroughly washed with diluted washing
buffer and 100 ml of enzyme conjugate was added into each well and incubated for
60min at room temperature. Following several washes, 200ml of pNPP substrate
solution was incubated at room temperature for 40min and the reactions were
stopped by addition of 50 ml of pNPP stop solution per well. The optical density of
each well was measured at 405 nm and a standard curve was plotted using a range
of known noradrenaline concentrations provided in the kit (0, 5, 15, 50, 150,
500 ngml 1). Positive and negative controls were included to determine accuracy.
The limit of sensitivity was 20 pgml 1 and the linearity limit was 8.0 ngml 1.
Cross-reactivity to other catecholamines or metabolites was manufacturer tested as
o0.02%. Protein concentrations of each sample was determined using the Brad-
ford dye-binding method (Bio-rad) and noradrenaline concentrations of each
sample was normalized to mg of protein and expressed as noradrenaline (ngmg 1
tissue protein)70.
Statistical analysis. Most experiments in this study involved four groups and
hence, a power analysis for a two-way analysis of variance design was used, based
on previously published data from the mouse ear model and hindpaw vasculature
12,13. For confidence at the 0.05 (5%) with power at 0.8 (80%) and the effect size of
medium (0.75), groups of n¼ 8 are recommended. In some experiments where a
difference was clearly distinct, the experiment was unblinded for analysis (sample
size 44) to minimize animal use.
Results are expressed as mean±s.e.m. Data statistical analysis was performed
using a two-tailed Student’s t-test or two-way analysis of variance followed by
Bonferroni’s comparison post hoc test. Po0.05 was considered to represent a
significant difference.
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